Monte Rosa Therapeutics, Inc. (GLUE) Tops Q3 EPS by 18c
Tweet
Share
E-mailGet Alerts GLUE Hot Sheet
Join SI Premium – FREE
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) reported Q3 EPS of ($0.29), $0.18 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $9.22 million versus the consensus estimate of $2.61 million.
For earnings history and earnings-related data on Monte Rosa Therapeutics, Inc. (GLUE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- L3Harris CEO steps down amid conduct review, shares drop
- Evaxion adds brain cancer vaccine program, drops EVX-03
- Maxim Group Downgrades cbdMD Inc. (YCBD) to Hold
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
